Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASS-01: mFFX vs GA in Untreated Metastatic Pancreatic Cancer
NCT04469556Phase 2Completed
- Sponsor
- University Health Network
- Start
- Oct 2020
- Primary completion
- Mar 2025
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of FOLFIRINOX, gemcitabine, paclitaxel in pancreatic ductal adenocarcinoma (PDAC), sponsored by University Health Network. Started Oct 2020; status: completed.
02
Drugs
FOLFIRINOXgemcitabinepaclitaxel
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04469556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04469556.